Aptivus (Tipranavir)
| Brand Name: |
Aptivus |
| Generic Name: |
Tipranavir |
| Adult Single Dose: |
Two 250-mg capsules or 5-mL oral solution, taken with two 100-mg capsules of Norvir (twice a day) |
| Food & Liquid Restrictions: |
Can be taken with or without meals if the Norvir is in capsule or solution form. Must only be taken with meals if the Norvir is in tablet form. |
| Drug Class: |
PI |
|
|
|
The Basics
- Tipranavir Patient Assistance Program (Regularly Updated)
Can't afford this medication? Click the link above to see if you qualify for the patient assistance program or call 1-800-556-8317.
From RxHope
- An Overview of Aptivus (Tipranavir) (September 13, 2012)
From AIDSinfo
- Tipranavir (Aptivus) (August 26, 2012)
To read PDF, click here.
From AIDS InfoNet
- Aptivus (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Aptivus (Tipranavir) (PDF) (April 2011)
From Boehringer Ingelheim
- FAQs About Tipranavir (Aptivus) (October 19, 2009)
From The Body's "Ask the Experts" Forums
- Aptivus (Tipranavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Tipranavir: The First Nonpeptidic Protease Inhibitor (Winter 2003/2004)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Aptivus (Tipranavir): An In-Depth Look (Spring 2006)
Includes background information, study results, potential uses and side effects.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
News
- New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam (June 23, 2008)
From U.S. Food and Drug Administration
- U.S. FDA Approves New Anti-HIV Drug Aptivus for Use in Combination Therapy (June 23, 2005)
From Boehringer Ingelheim
- FDA Approval of Aptivus (Tipranavir) (June 23, 2005)
From U.S. Food and Drug Administration
- Tipranavir (Aptivus): Approval Cautiously Recommended (June 20, 2005)
In AIDS Treatment News, from AIDS Treatment News
- Large Tipranavir Trials Open (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tipranavir Patients May Experience Intracranial Hemorrhage, FDA Warns (June 30, 2006)
From U.S. Food and Drug Administration
Research
- Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir (September 15, 2010)
From National AIDS Treatment Advocacy Project
- New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
- A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- A Thorough Look at Tipranavir Based on Studies Assessing Its Efficacy, Resistance and Safety (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance (August 17, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Use of Tipranavir for Patients With Little Prior PI Experience (August 15, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Tipranavir Update at CROI 2006: RESIST Study Results, Drug Interactions and Therapeutic Drug Monitoring (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
On TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
